HEPION PHARMACEUTICALS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
HEPION PHARMACEUTICALS, INC. (HEPA) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$1.15 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-15
- HEPION PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$1.15M.
- HEPION PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$6.20M.
- HEPION PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $6.45M.
- HEPION PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$1.42M, a 120.71% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$3.12M.
- HEPION PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $5.58M, a 96.38% increase from fiscal 2016.
- HEPION PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $2.84M, a 3.47% increase from fiscal 2015.
- HEPION PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $2.75M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-03-31 | -$1.15M 10-Q · filed 2019-05-15 | -$7.35M derived: sum of 2 quarters · filed 2019-05-15 | -$897.75K derived: sum of 3 quarters · filed 2019-05-15 | -$2.32M derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-12-31 | -$6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $252.07K derived: sum of 2 quarters · filed 2019-03-14 | -$1.17M derived: sum of 3 quarters · filed 2019-03-14 | -$3.12M 10-K · filed 2019-03-14 |
| 2018-09-30 | $6.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $5.03M derived: sum of 2 quarters · filed 2018-11-14 | $3.08M 10-Q · filed 2018-11-14 | $253.57K derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-06-30 | -$1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$3.37M 10-Q · filed 2018-08-14 | -$6.20M derived: sum of 3 quarters · filed 2019-05-15 | -$10.40M derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-03-31 | -$1.96M 10-Q · filed 2019-05-15 | -$4.78M derived: sum of 2 quarters · filed 2019-05-15 | -$8.98M derived: sum of 3 quarters · filed 2019-05-15 | -$2.14M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | -$2.82M derived: 10-K 6 month − 10-Q 3 month · filed 2019-03-14 | -$7.03M 10-K · filed 2019-03-14 | -$183.45K derived: sum of 3 quarters · filed 2019-03-14 | -$4.60M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-09-30 | -$4.20M 10-Q · filed 2017-11-14 | $2.64M derived: sum of 2 quarters · filed 2018-08-14 | -$1.77M 10-Q · filed 2018-11-14 | $5.75M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-06-30 | $6.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $2.43M 10-Q · filed 2018-08-14 | $9.95M derived: sum of 3 quarters · filed 2018-08-14 | $5.58M 10-K · filed 2019-03-14 |
| 2017-03-31 | -$4.41M 10-Q · filed 2018-05-15 | $3.11M derived: sum of 2 quarters · filed 2018-05-15 | -$1.27M 10-Q · filed 2017-04-12 | $180.70K derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $7.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-14 | $3.15M 10-Q · filed 2017-02-14 | $4.59M derived: sum of 3 quarters · filed 2018-03-26 | $719.40K derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-09-30 | -$4.38M 10-Q · filed 2017-11-14 | -$2.93M derived: sum of 2 quarters · filed 2018-03-26 | -$6.80M derived: sum of 3 quarters · filed 2018-03-26 | $1.24M derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-06-30 | $1.45M derived: 10-KT 12 month − 10-Q 9 month · filed 2018-03-26 | -$2.43M derived: sum of 2 quarters · filed 2018-03-26 | $5.61M derived: sum of 3 quarters · filed 2018-03-26 | $2.84M 10-KT · filed 2018-03-26 |
| 2016-03-31 | -$3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-04-12 | $4.17M derived: sum of 2 quarters · filed 2017-04-12 | $1.39M 10-Q · filed 2017-04-12 | |
| 2015-12-31 | $8.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-14 | $5.27M 10-Q · filed 2017-02-14 | ||
| 2015-09-30 | -$2.77M 10-Q · filed 2016-11-14 | |||
| 2015-06-30 | $2.75M 10-K · filed 2016-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |